These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1373 related items for PubMed ID: 19835828
1. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G. Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828 [Abstract] [Full Text] [Related]
2. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L. J Infect Dis; 2010 Jun 01; 201(11):1644-53. PubMed ID: 20423222 [Abstract] [Full Text] [Related]
3. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P. Pediatr Infect Dis J; 2010 Jun 01; 29(6):e35-46. PubMed ID: 20375709 [Abstract] [Full Text] [Related]
4. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605 [Abstract] [Full Text] [Related]
5. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L. Vaccine; 2011 Aug 26; 29(37):6408-18. PubMed ID: 21554915 [Abstract] [Full Text] [Related]
7. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, Bock HL, Dramé M, Gillard P, Hutagalung Y, Tang H, Teoh YL, Ballou RW, H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand. Vaccine; 2009 Dec 09; 27(52):7428-35. PubMed ID: 19683087 [Abstract] [Full Text] [Related]
8. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP. Clin Infect Dis; 2009 Apr 15; 48(8):1087-95. PubMed ID: 19281330 [Abstract] [Full Text] [Related]
9. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC. Vaccine; 2008 Nov 25; 26(50):6383-91. PubMed ID: 18801398 [Abstract] [Full Text] [Related]
13. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. Vaccine; 2012 Sep 21; 30(43):6127-35. PubMed ID: 22884662 [Abstract] [Full Text] [Related]
14. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. Clin Infect Dis; 2010 Sep 15; 51(6):668-77. PubMed ID: 20687838 [Abstract] [Full Text] [Related]
17. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G. Vaccine; 2012 May 14; 30(23):3470-7. PubMed ID: 22446638 [Abstract] [Full Text] [Related]
20. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li CG, Zhou JC, Fang HH, Liu Y, Liu LY, Qiu YZ, Gao Q, Zhang XM, Chen JT, Zhong X, Yin WD, Feng ZJ. Vaccine; 2010 Aug 31; 28(38):6221-7. PubMed ID: 20638454 [Abstract] [Full Text] [Related] Page: [Next] [New Search]